Kymera Results Presentation Deck

Oncology KT-333 and KT-413 Phase 1 trials in dose escalation phase Both molecules demonstrating PK/PD consistent with pre-clinical models No dose-limiting toxicities observed to date KT-253 IND cleared; Phase 1 trial expected to commence in early 2023 ● ● ● Presentation Summary KT-474 Part C cohort complete: data supportive of promising clinical and market opportunities in HS and AD PK/PD in patients in line with healthy volunteers with broad impact on disease relevant cytokines in blood and skin of HS and AD patients ● KT-474 generally well-tolerated; QTc spontaneously returned to normal baseline during the dosing period Clinical endpoints suggest promising potential in both HS and AD, supporting targeting IRAK4 and clear differentiation of degrader versus small molecule inhibitors Sanofi officially committed to advance KT-474 into Phase 2 clinical trials, initially in HS and AD KYMERA ©2022 KYMERA THERAPEUTICS, INC. ● PAGE 6

View entire presentation